The company reported encouraging Phase 2 clinical data for its lead candidate silevertinib with promising progression-free survival results, beat Q1 earnings estimates, and has sufficient cash runway into H2 2028. Analyst consensus maintains a Buy rating with $11.00 average price target, suggesting confidence in the pipeline despite near-term technical weakness.
The company announced positive Phase 2 trial results for its lead candidate silevertinib, demonstrating strong efficacy metrics including 60% ORR, 15.2 months mPFS, and robust CNS activity with 86% CNS ORR. The absence of de novo brain metastases in patients further supports the drug's brain-penetrant design, indicating promising clinical progress for a clinical-stage oncology company.
Articles that tag BDTX but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
